Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
S125098-250mg
|
250mg |
3
|
$9.90
|
|
|
S125098-1g
|
1g |
3
|
$19.90
|
|
|
S125098-5g
|
5g |
3
|
$28.90
|
|
|
S125098-25g
|
25g |
2
|
$99.90
|
|
|
S125098-100g
|
100g |
2
|
$279.90
|
|
Potent multikinase inhibitor
| Synonyms | 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide | SCHEMBL8218 | L01XE05 | NSC7177 | UNII-9ZOQ3TZI87 | NSC747971 | NSC-747971 | BAY 439006 | BAY 43-9006 | 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]ca |
|---|---|
| Specifications & Purity | Moligand™, ≥99% |
| Biochemical and Physiological Mechanisms | Sorafenib is a RAF kinase inhibitor which suppresses ERK phosphorylation. Studies indicate that sorafenib induces c-Raf phosphorylation at both Ser-43 and Ser-259. When combined with vitamin K1, phosphorylation is increased at these serine residues. Soraf |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Grade | Moligand™ |
| Action Type | INHIBITOR |
| Mechanism of action | Inhibitor of B-Raf proto-oncogene; serine/threonine kinase;Inhibitor of cyclin dependent kinase 19;Inhibitor of cyclin dependent kinase 8;Inhibitor of discoidin domain receptor tyrosine kinase 2;Inhibitor of fibroblast growth factor receptor 1;Inhibitor o |
| Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
| Product Description |
Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia. |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic oxygen compounds |
| Class | Organooxygen compounds |
| Subclass | Ethers |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Diarylethers |
| Alternative Parents | Trifluoromethylbenzenes N-phenylureas Pyridinecarboxamides Phenoxy compounds Phenol ethers 2-heteroaryl carboxamides Chlorobenzenes Aryl chlorides Heteroaromatic compounds Ureas Secondary carboxylic acid amides Azacyclic compounds Organopnictogen compounds Organonitrogen compounds Organofluorides Organochlorides Organic oxides Hydrocarbon derivatives Carbonyl compounds Alkyl fluorides |
| Molecular Framework | Aromatic heteromonocyclic compounds |
| Substituents | Diaryl ether - Trifluoromethylbenzene - N-phenylurea - Pyridine carboxylic acid or derivatives - Pyridinecarboxamide - 2-heteroaryl carboxamide - Phenoxy compound - Phenol ether - Halobenzene - Chlorobenzene - Benzenoid - Pyridine - Monocyclic benzene moiety - Aryl halide - Aryl chloride - Heteroaromatic compound - Urea - Secondary carboxylic acid amide - Carbonic acid derivative - Carboxamide group - Azacycle - Organoheterocyclic compound - Carboxylic acid derivative - Organic nitrogen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Organonitrogen compound - Organofluoride - Organochloride - Organohalogen compound - Carbonyl group - Alkyl halide - Alkyl fluoride - Aromatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. |
| External Descriptors | aromatic ether - ureas - monochlorobenzenes - (trifluoromethyl)benzenes - pyridinecarboxamide |
|
|
|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IUPAC Name | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide |
|---|---|
| INCHI | InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31) |
| InChIKey | MLDQJTXFUGDVEO-UHFFFAOYSA-N |
| Smiles | CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F |
| Isomeric SMILES | CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F |
| Molecular Weight | 464.83 |
| Reaxy-Rn | 9666200 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9666200&ln= |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jun 10, 2025 | S125098 | |
| Certificate of Analysis | May 13, 2025 | S125098 | |
| Certificate of Analysis | Sep 19, 2024 | S125098 | |
| Certificate of Analysis | Sep 19, 2024 | S125098 | |
| Certificate of Analysis | Sep 19, 2024 | S125098 | |
| Certificate of Analysis | Jun 17, 2024 | S125098 | |
| Certificate of Analysis | Dec 20, 2023 | S125098 | |
| Certificate of Analysis | Dec 20, 2023 | S125098 | |
| Certificate of Analysis | Dec 20, 2023 | S125098 | |
| Certificate of Analysis | Dec 19, 2023 | S125098 | |
| Certificate of Analysis | Dec 19, 2023 | S125098 | |
| Certificate of Analysis | Dec 19, 2023 | S125098 | |
| Certificate of Analysis | Dec 19, 2023 | S125098 | |
| Certificate of Analysis | Dec 19, 2023 | S125098 | |
| Certificate of Analysis | Dec 19, 2023 | S125098 | |
| Certificate of Analysis | Dec 19, 2023 | S125098 | |
| Certificate of Analysis | Dec 19, 2023 | S125098 | |
| Certificate of Analysis | Jun 07, 2023 | S125098 | |
| Certificate of Analysis | Oct 26, 2022 | S125098 | |
| Certificate of Analysis | Oct 26, 2022 | S125098 | |
| Certificate of Analysis | Jul 11, 2022 | S125098 | |
| Certificate of Analysis | Dec 24, 2021 | S125098 |
| Solubility | Soluble in DMSO (~20 mg/ml), Hot Methanol, DMF (~20 mg/ml), 1:2 solution of DMSO:PBS(PH 7.2 ) (~0.3 mg/ml), 100% ethanol, and ethyl acetate. |
|---|---|
| Sensitivity | heat sensitive;air sensitive |
| Molecular Weight | 464.800 g/mol |
| XLogP3 | 4.100 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Exact Mass | 464.086 Da |
| Monoisotopic Mass | 464.086 Da |
| Topological Polar Surface Area | 92.400 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 646.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
Starting at $554.90
| 1. Xi Chen, Ning Zhu, Yajie Wu, Ye Zhang, Yuxuan Zhang, Kaiwen Jin, Zhiyi Zhou, Guang Chen, Jiabing Wang. (2023) Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells. PHYTOMEDICINE, (155317). |
| 2. Qinglian Hu, Liwang Xu, Xiaoyu Huang, Yuxuan Duan, Dongchang Sun, Zhengwei Fu, Yunfen Ge. (2023) Polydopamine-Modified Zeolite Imidazole Framework Drug Delivery System for Photothermal Chemotherapy of Hepatocellular Carcinoma. BIOMACROMOLECULES, 24 (12): (5964–5976). |
| 3. Ye Yuan, Chunyu Tian, Qi Wang, Xinyu Qiu, Yufang Wang, Hulin Jiang, Jifu Hao, Yujing He. (2023) Synergistic Amplification of Ferroptosis with Liposomal Oxidation Catalyst and Gpx4 Inhibitor for Enhanced Cancer Therapy. Advanced Healthcare Materials, (2301292). |
| 4. Peifeng Wang, Yang Du, Xingyang Zhao, Yueyang Hu, Tianjun Zhou, Xiaolong Liang, Chihua Fang, Jie Tian. (2023) 2-Methoxyestradiol loaded mesoporous polydopamine nanoprobes for hypoxia alleviation and sorafenib synergistic treatment of hepatocellular carcinoma. MATERIALS & DESIGN, 232 (112137). |
| 5. Yufei Pan, Jing Guan, Yujing Gao, Yuejie Zhu, Huantong Li, Hua Guo, Qianyi He, Zhu Guan, Zhenjun Yang. (2023) Modified ASO conjugates encapsulated with cytidinyl/cationic lipids exhibit more potent and longer-lasting anti-HCC effects. Molecular Therapy-Nucleic Acids, 32 (807-821). |
| 6. Jing-Qing Le, Fang Yang, Xun-Huan Song, Ke-Ke Feng, Ling-Wu Tong, Meng-Die Yin, Wen-Zhong Zhang, Ying-Qi Lin, Hui Wu, Jing-Wei Shao. (2023) A hemoglobin-based oxygen-carrying biomimetic nanosystem for enhanced chemo-phototherapy and hypoxia alleviation of hepatocellular carcinoma. JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY, 123 (330). |
| 7. Yao Li, Mengying Liu, Yan Zheng, Zheng Wang, Yanjun Zhao. (2023) Coenzyme-depleting nanocarriers for enhanced redox cancer therapy under hypoxia. JOURNAL OF COLLOID AND INTERFACE SCIENCE, 641 (135). |
| 8. Shuai Wang, Jian-Tao Shi, Xing-Rong Wang, Hong-Xia Mu, Xue-Ting Wang, Kai-Yan Xu, Qing-Shan Wang, Shi-Wu Chen. (2023) 1H-Indazoles derivatives targeting PI3K/AKT/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism. BIOORGANIC CHEMISTRY, 133 (106412). |
| 9. Chunmei Lai, Bingchen Zhang, Dongmiao Li, Xiarong Tan, Bangyue Luo, Jiangwen Shen, Linyan Li, Jingwei Shao. (2023) Rational design of a minimum nanoplatform for maximizing therapeutic potency: Three birds with one stone. JOURNAL OF COLLOID AND INTERFACE SCIENCE, 635 (441). |
| 10. Hu Xiaomeng, He Yuchao, Han Zhiqiang, Liu Wei, Liu Dongming, Zhang Xihao, Chen Lu, Qi Lisha, Chen Liwei, Luo Yi, Li Qiang, Chen Peng, Wu Qiang, Zhu Xiaolin, Guo Hua. (2022) PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma. Cell Death & Disease, 13 (11): (1-12). |
| 11. Xing-Rong Wang, Shuai Wang, Hong-Xia Mu, Kai-Yan Xu, Xue-Ting Wang, Jian-Tao Shi, Qi-Hang Cui, Li-Wen Zhang, Shi-Wu Chen. (2022) Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 244 (114821). |
| 12. Wang Chonggao, Cheng Xiaolan, Peng Hao, Zhang Yewei. (2022) NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma. Nanoscale Research Letters, 17 (1): (1-16). |
| 13. An-Tian Huang, Jun Du, Zhi-Yong Liu, Guang-Cong Zhang, Weinire Abuduwaili, Jia-Yan Yan, Jia-Lei Sun, Ru-Chen Xu, Tao-Tao Liu, Xi-Zhong Shen, Ling Dong, Ji-Min Zhu, Yuhao Li. (2022) Sorafenib-Loaded Cu2−xSe Nanoparticles Boost Photothermal–Synergistic Targeted Therapy against Hepatocellular Carcinoma. Nanomaterials, 12 (18): (3191). |
| 14. Liyue Zhou, Qiangwei Liang, Yifan Li, Yongjing Cao, Juan Li, Jiayu Yang, Jinxia Liu, Jiawei Bi, Yanhua Liu. (2022) Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy. Acta Biomaterialia, 152 (235). |
| 15. Wenjie Feng, Wanrui Shi, Ze Wang, Yanqi Cui, Xinxin Shao, Shuwei Liu, Li Rong, Yi Liu, Hao Zhang. (2022) Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification. ACS Applied Materials & Interfaces, 14 (33): (37540–37552). |
| 16. Zaigang Zhou, Jiashe Chen, Yu Liu, Chunjuan Zheng, Wenjuan Luo, Lele Chen, Shen Zhou, Zhiming Li, Jianliang Shen. (2022) Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy. Acta Pharmaceutica Sinica B, 12 (4204). |
| 17. Chen Zibo, Yuan Tao, Yan Fangjie, Ye Song, Xie Qin, Zhang Bo, Lin Nengmin, He Qiaojun, Yang Bo, Zhu Hong. (2022) CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling. BMC CANCER, 22 (1): (1-9). |
| 18. Yuehua Wang, Zhenjie Wang, Fei Jia, Qing Xu, Zhilin Shu, Junlin Deng, Aimin Li, Meng Yu, Zhiqiang Yu. (2022) CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment. Bioactive Materials, 17 (147). |
| 19. Jie Cui, Jiatao Liu, Lulu Fan, Yue Zhu, Bei Zhou, Yu Wang, Wei Hua, Wei Wei, Guoping Sun. (2020) A zinc finger family protein, ZNF263, promotes hepatocellular carcinoma resistance to apoptosis via activation of ER stress-dependent autophagy. Translational Oncology, 13 (100851). |
| 20. Longfa Kou, Rui Sun, Xinyu Jiang, Xinlu Lin, Huirong Huang, Shihui Bao, Youting Zhang, Chao Li, Ruijie Chen, Qing Yao. (2020) Tumor Microenvironment-Responsive, Multistaged Liposome Induces Apoptosis and Ferroptosis by Amplifying Oxidative Stress for Enhanced Cancer Therapy. ACS Applied Materials & Interfaces, 12 (27): (30031–30043). |
| 21. Haiqiu Wu, Cun Wang, Jiaxin Sun, Luyan Sun, Jiaxun Wan, Siying Wang, Dishui Gu, Chengtao Yu, Chen Yang, Jia He, Zihao Zhang, Yuanyuan Lv, Hui Wang, Ming Yao, Wenxin Qin, Changchun Wang, Haojie Jin. (2019) Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis. ACS Applied Materials & Interfaces, 11 (47): (43996–44006). |
| 22. Wenhui Gao, Xiaoting Jia, Jinjun Wu, Ying Song, Jiang Yin, Meimei Zhang, Ni Qiu, Xiaoyan Li, Peng Wu, Xiaoxiao Qi, Zhongqiu Liu. (2019) Preparation and evaluation of folate-decorated human serum albumin nanoparticles for the targeted delivery of sorafenib to enhance antihepatocarcinoma efficacy. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 54 (101349). |
| 23. Lu Bin, Chen Xiao-bing, Hong Yu-cai, Zhu Hong, He Qiao-jun, Yang Bo, Ying Mei-dan, Cao Ji. (2019) Identification of PRDX6 as a regulator of ferroptosis. ACTA PHARMACOLOGICA SINICA, 40 (10): (1334-1342). |
| 24. Jun-Shan Liu, Chu-Ying Huo, Hui-Hui Cao, Chun-Lin Fan, Jian-Yang Hu, Li-Juan Deng, Zi-Bin Lu, Hua-Yi Yang, Lin-Zhong Yu, Zhi-Xian Mo, Zhi-Ling Yu. (2019) Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway. PHYTOMEDICINE, 61 (152843). |
| 25. Gao Ningning, Zhong Jingjing, Wang Xiaodong, Jin Zhenchao, Li Wang, Liu Yu, Diao Yuwen, Wang Zhulin, Jiang Wenqi, Jin Guangyi. (2016) Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib. Scientific Reports, 6 (1): (1-9). |
| 26. Ji Cao, Xiaobing Chen, Li Jiang, Bin Lu, Meng Yuan, Difeng Zhu, Hong Zhu, Qiaojun He, Bo Yang, Meidan Ying,. (2020-03-08) DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase.. Nature communications, 11 ((1)): ( 1251-1251 ). |
| 27. Chun-Mei Lai, Jia Xu, Bing-Chen Zhang, Shao-Hua He, Jing-Wei Shao. (2024) A natural product-derived nanozyme regulator induced chemo-ferroptosis dual therapy in remodeling of the tumor immune microenvironment of hepatocellular carcinoma. CHEMICAL ENGINEERING JOURNAL, 482 (148976). |
| 28. Wenlong Huang, Bo Jin, Haobing Gong, Nawab Ali, Duoduo Jiang, Tongtong Shan, Liangshun Zhang, Jia Tian, Weian Zhang. (2024) A tumor Microenvironment-triggered protein-binding Near-infrared-II Theranostic nanoplatform for Mild-Temperature photothermal therapy. JOURNAL OF COLLOID AND INTERFACE SCIENCE, |
| 29. Taosha Jin, Haiyang Wang, Ihsan Ullah, Wenjiao Xie, Taian Lin, Qiaoling Tan, Xiaoyu Pan, Youyong Yuan. (2025) A Wireless Operated Flexible Bioelectronic Microneedle Patch for Actively Controlled Transdermal Drug Delivery. ADVANCED MATERIALS, (2417136). |
| 30. Hongwei Xiang, Bin Shen, Chunmei Zhang, Rui Li. (2024) Bioactive Nanoliposomes for Enhanced Sonodynamic-Triggered Disulfidptosis-Like Cancer Cell Death via Lipid Peroxidation. International Journal of Nanomedicine, |
| 31. Yuanxin Pian, Yan Hao, Yuxin Guo, Shiqi Wu, Saijiao Tang, Jiaqi Li, Xinya Lu, Xiaoya Sun, Zhaowen Tan, Tianyu Zhu, Yuxiang Tang, Defeng Xu, Hang Hu. (2025) Exploration of using α-crocin for drug encapsulation and delivery. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 106 (106716). |
| 32. Xiaoxuan Li, Hongyun Zhang, Yufei Deng, Fang qian, Xiaohui Zhang, Shuiping Ding, Xiaoying Hou, Hongzhi Du. (2024) Huaier polysaccharides inhibits hepatocellular carcinoma via gut microbiota mediated M2 macrophage polarization. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, (139357). |
| 33. Yonggang Lv, Zhenghang Chen, Shuai Wang, Meizhen Zou. (2025) Macrophage-Mediated Liquid Metal Nanoparticles for Enhanced Tumor Accumulation and Inhibition. ACS Biomaterials Science & Engineering, |
| 34. Rui-Rui Zhao, Ju-Hong Wu, Ling-Wu Tong, Jin-Yu Li, Yu-sheng Lu, Jing-Wei Shao. (2024) Multifunctional Metal-coordinated Co-assembled Carrier-free Nanoplatform Based on Dual-drugs for Ferroptosis-mediated Cocktail Therapy of Hepatocellular Carcinoma Growth and Metastasis. JOURNAL OF COLLOID AND INTERFACE SCIENCE, |
| 35. Fanqi Meng, Lei Chen, Haoran Chen, Meili Shen, Guangyi Wang, Yulei Chang. (2024) Multiple Stimuli-Responsive Micelles for Photo/ROS/pH-Triggered Chemo/Photo/Ferroptosis Therapy of Colorectal Cancer. ACS Applied Nano Materials, 7 (22): (25995-26005). |
| 36. Xing Gao, Hongwei Cheng, Minglei Teng, Hongrui Zhang, Hu Chen, Songnan Qu, Gang Liu. (2025) Optimizing interventional therapy: A homogeneous lipiodol formulation of Tirapazamine and Sorafenib responsive to post-embolization microenvironment. JOURNAL OF CONTROLLED RELEASE, 379 (879). |
| 37. Shunli Yu, Ruhe Zhang, Zhaoxiang Xie, Zhi Xiong, Shirong Peng, Bingheng Li, Ruilin Zhuang, Jun Wu, Hai Huang. (2024) Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy. ACS Biomaterials Science & Engineering, 10 (7): (4336-4346). |
| 38. Lu-Yao Zheng, Yan-Xin Da, Xiu Luo, Xiao Zhang, Zhi-Jie Sun, De-Li Dong. (2024) Sorafenib extends the lifespan of C. elegans through mitochondrial uncoupling mechanism. FREE RADICAL BIOLOGY AND MEDICINE, 214 (101). |
| 39. Zhenghao Zhou, Cong Li, Shuai Cui, Shian Sun, Shaowei Zhu, Qing Yu, Ning Ding, Hao Hong, Dongzhi Yang. (2024) Synergistic therapy for melanoma via bioactive compounds derived metal-phenolic networks. CHEMICAL ENGINEERING JOURNAL, 488 (150831). |
| 40. Chunfang Qin, Hao Wang, Hongyan Cui, Yue Wang, Ming Zhang, Haidong Li, Yuchen Liu, Jingyun Wang, Qixian Chen, Yan Zhao. (2024) Synthetic genomic nanomedicine with triple-responsiveness for systemic anti-tumor therapy. JOURNAL OF COLLOID AND INTERFACE SCIENCE, 672 (350). |
| 41. Li Xiang, Yuting Qin, Lei Li, Xianjing Xiang, Wenhui Zhang, Qiangqiang Jiao, Yaru Shao, Xinqiong Huang, Meichun Wu, Tianle Zhou, Yukang Lin, Yuping Chen. (2024) Targeting hyperactive mitochondria in activated HSCs and inhibition of liver fibrogenesis in mice using sorafenib complex micelles. INTERNATIONAL JOURNAL OF PHARMACEUTICS, (125058). |